Immutep Announces Update From Placebo-Controlled, Double-Blind First-In-Human Phase I Study In Healthy Participants Evaluating IMP761 For Autoimmune Diseases

Immutep Limited has completed the single ascending dose (SAD) portion of its Phase I study for IMP761, a first-in-class LAG-3 agonist antibody, with dosing up to 14 mg/kg showing good tolerance and no safety concerns. The study is now advancing to the multiple ascending dose (MAD) portion, which will assess pharmacokinetics and safety, expected to be completed in Q3 2026. Results from the Phase I study will be presented at the EULAR conference on June 4, 2026.